Pretransplant comprehensive scores to predict long term graft outcomes

移植前综合评分可预测长期移植结果

基本信息

  • 批准号:
    10679624
  • 负责人:
  • 金额:
    $ 20.75万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-03-16 至 2025-02-28
  • 项目状态:
    未结题

项目摘要

Despite the improved short-term outcomes in kidney transplantation (KT), comparable progress in long-term allograft survival has not been achieved. Chronic allograft dysfunction (CAD) characterized by interstitial fibrosis and tubular atrophy (IFTA), accounts for one quarter of transplant kidneys lost within 5 years. Preventing kidney graft dysfunction and loss is a critical unmet need in transplantation. From reported evidence, posttransplant graft survival is determined by the complex interplay of donor factors, acute peri-transplantation injury, and kidney transplant recipient factors. We recently reported that the transcriptome of deceased donor kidneys encompasses a gene signature at the time of KT that predicts long-term graft function. These signatures shed light on the inherent donor mechanisms responsible for triggering and likely sustaining posttransplant injury. Furthermore, although a recipient peripheral blood transcriptional signature was recently reported as a predictor of early acute rejection, the effect of pretransplant KT recipient peripheral blood transcriptional profiles on long- term outcomes has not been previously tested. Moreover, there are no comprehensive biological markers from donors and recipients that can be used pretransplant to predict graft outcomes. Given the multifactorial nature of CAD, our preliminary data, and the gaps in our knowledge, we have the unique ability to fill these unmet needs by studying the early stressors that lead to kidney graft fibrosis deploying an unbiased comprehensive approach. Towards this goal, we have already established a cohort with prospective sequential sampling of kidney allografts. In our studies, donor kidneys were evaluated at pre-implantation and recipient pretransplant peripheral blood mononuclear cells (PBMCs) were collected. The recipient cohort also includes longitudinal PBMCs, protocol biopsies, and detailed clinical metadata, allowing for the correlation of gene expression profiles with histological features and clinical parameters. In this exploratory proposal, we hypothesize that early cellular and molecular events in the donor kidney trigger local inflammatory responses that, when combined with recipient immune state, propagate and sustain posttransplant kidney injury leading to graft loss. Specific aims (SA) include: SA1 (1) Identify kidney transplant recipient preimplantation peripheral blood molecular profiles that associate with immune activation vs quiescence and determine posttransplant graft function. (2) Discern longitudinal posttransplant molecular variations in patient's PBMCs that associate with long-term graft function. SA2 Integrate kidney donor and recipient peripheral blood gene expression profiles in association with donor/recipient clinical characteristics for constructing a composite score to predict long-term outcomes. IMPACT: Results of these studies will provide a unique understanding of the early molecular triggers that determine graft outcomes and ultimately lead to CAD. Novel prognostic biomarkers will enable the early identification of patients at higher risk for progression to CAD, allowing for the development of new therapeutic modalities that have the potential to avoid irreversible graft injury and improve long-term outcomes.
尽管肾移植(KT)的短期结果有所改善,但长期进展与之相当 同种异体移植物的存活率尚未达到。以间质纤维化为特征的慢性移植物功能障碍(CAD) 和肾小管萎缩(IFTA),占移植肾在5年内丢失的四分之一。预防肾脏 移植物功能障碍和丢失是移植中一个严重的未得到满足的需求。从报告的证据来看,移植后 移植物存活率由供体因素、急性移植周损伤和 肾移植受者因素。我们最近报道了已故供体肾脏的转录组 包括KT时的一个基因签名,它预测了移植物的长期功能。这些签名丢掉了 阐明导致并可能维持移植后损伤的内在供体机制。 此外,尽管最近报道受者外周血转录特征是一种预测因素 移植前KT受者外周血转录水平对早期急性排斥反应的影响 任期结果之前从未接受过测试。此外,还没有全面的生物标记 来自供者和受者的数据,可以在移植前用来预测移植结果。给出了多因素 CAD的性质,我们的初步数据,以及我们知识中的空白,我们有独特的能力来填补这些未满足的 通过研究导致移植肾纤维化的早期应激源来满足需求 接近。为了实现这一目标,我们已经建立了一个队列,采用前瞻性序贯抽样 异体肾移植。在我们的研究中,供体肾脏在植入前和受者移植前进行了评估。 采集外周血单个核细胞(PBMC)。接受者队列还包括纵向 PBMC、常规活组织检查和详细的临床元数据,允许基因表达谱的相关性 有组织学特征和临床参数。在这个探索性的方案中,我们假设早期的细胞 供体肾脏中的分子事件会引发局部炎症反应,当与 受体处于免疫状态,传播并维持移植后肾损伤,导致移植物丢失。具体目标 (Sa)包括:SA1(1)确定肾移植受者植入前的外周血液分子图谱 与免疫激活和静止相关联,并决定移植后的移植物功能。(2)洞察力 移植后患者PBMCs中与长期移植功能相关的纵向分子变化。 SA2整合肾供受者外周血基因表达谱与 供者/受者的临床特征,用于构建预测长期结果的综合评分。 影响:这些研究的结果将提供对早期分子触发因素的独特理解 决定移植物的结果并最终导致冠心病。新的预后生物标志物将使早期 识别进展为冠心病风险较高的患者,从而开发新的治疗方法 有可能避免不可逆转的移植物损伤并改善长期结果的方法。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Kellie J. Archer其他文献

Regularized Mixture Cure Models Identify a Gene Signature That Improves Risk Stratification within the Favorable-Risk Group in 2017 European Leukemianet (ELN) Classification of Acute Myeloid Leukemia (Alliance 152010)
  • DOI:
    10.1182/blood-2022-166477
  • 发表时间:
    2022-11-15
  • 期刊:
  • 影响因子:
  • 作者:
    Kellie J. Archer;Han Fu;Krzysztof Mrózek;Deedra Nicolet;Jessica Kohlschmidt;Alice S. Mims;Geoffrey L. Uy;Wendy Stock;John C. Byrd;Ann-Kathrin Eisfeld
  • 通讯作者:
    Ann-Kathrin Eisfeld
Characterization of Survival Outcomes and Clinical and Molecular Modulators in Adult Patients with Core-Binding Factor Acute Myeloid Leukemia (CBF-AML) Treated with Hidac Consolidation: An Alliance Legacy Study
  • DOI:
    10.1182/blood-2022-167210
  • 发表时间:
    2022-11-15
  • 期刊:
  • 影响因子:
  • 作者:
    Jonathan Hyak;Deedra Nicolet;Jessica Kohlschmidt;Kellie J. Archer;James S. Blachly;Karilyn T. Larkin;Bayard L. Powell;Jonathan E. Kolitz;Maria R. Baer;William G. Blum;Geoffrey L. Uy;Wendy Stock;Richard M. Stone;John C. Byrd;Krzysztof Mrózek;Ann-Kathrin Eisfeld;Alice S. Mims
  • 通讯作者:
    Alice S. Mims
Comparing genetic profiles of embryonic day 9 (E9) mouse yolk sac erythroid and erythroid and epithelial cells isolated by microdissection
  • DOI:
    10.1016/j.bcmd.2006.10.124
  • 发表时间:
    2007-03-01
  • 期刊:
  • 影响因子:
  • 作者:
    Latasha C. Redmond;Jack L. Haar;Catherine I. Dumur;Kellie J. Archer;Priyadarshi Basu;Joyce A. Lloyd
  • 通讯作者:
    Joyce A. Lloyd
Beat-AML 2024 ELN–refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy
  • DOI:
    10.1182/bloodadvances.2024013685
  • 发表时间:
    2024-10-22
  • 期刊:
  • 影响因子:
  • 作者:
    Fieke W. Hoff;William G. Blum;Ying Huang;Rina Li Welkie;Ronan T. Swords;Elie Traer;Eytan M. Stein;Tara L. Lin;Kellie J. Archer;Prapti A. Patel;Robert H. Collins;Maria R. Baer;Vu H. Duong;Martha L. Arellano;Wendy Stock;Olatoyosi Odenike;Robert L. Redner;Tibor Kovacsovics;Michael W. Deininger;Joshua F. Zeidner
  • 通讯作者:
    Joshua F. Zeidner
Outcome Prediction By the New 2022 European Leukemia Net (ELN) Genetic-Risk Classification for Adult Patients (Pts) with Acute Myeloid Leukemia (AML): An Alliance Study
  • DOI:
    10.1182/blood-2022-167352
  • 发表时间:
    2022-11-15
  • 期刊:
  • 影响因子:
  • 作者:
    Krzysztof Mrózek;Jessica Kohlschmidt;James S. Blachly;Deedra Nicolet;Andrew J. Carroll;Kellie J. Archer;Alice S. Mims;Karilyn T. Larkin;Shelley Orwick;Christopher C. Oakes;Jonathan E. Kolitz;Bayard L. Powell;William G. Blum;Guido Marcucci;Maria R. Baer;Geoffrey L. Uy;Wendy Stock;John C. Byrd;Ann-Kathrin Eisfeld
  • 通讯作者:
    Ann-Kathrin Eisfeld

Kellie J. Archer的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Kellie J. Archer', 18)}}的其他基金

Penalized mixture cure models for identifying genomic features associated with outcome in acute myeloid leukemia
用于识别与急性髓系白血病结果相关的基因组特征的惩罚混合治疗模型
  • 批准号:
    10340087
  • 财政年份:
    2022
  • 资助金额:
    $ 20.75万
  • 项目类别:
Penalized mixture cure models for identifying genomic features associated with outcome in acute myeloid leukemia
用于识别与急性髓系白血病结果相关的基因组特征的惩罚混合治疗模型
  • 批准号:
    10544523
  • 财政年份:
    2022
  • 资助金额:
    $ 20.75万
  • 项目类别:
Assessment of Donor Quality for Improving Kidney Transplant Outcomes
评估捐献者质量以改善肾移植结果
  • 批准号:
    9262665
  • 财政年份:
    2017
  • 资助金额:
    $ 20.75万
  • 项目类别:
Assessment of Donor Quality for Improving Kidney Transplant Outcomes
评估捐献者质量以改善肾移植结果
  • 批准号:
    10203464
  • 财政年份:
    2017
  • 资助金额:
    $ 20.75万
  • 项目类别:
Assessment of Donor Quality for Improving Kidney Transplant Outcomes
评估捐献者质量以改善肾移植结果
  • 批准号:
    9753687
  • 财政年份:
    2017
  • 资助金额:
    $ 20.75万
  • 项目类别:
Informatic tools for predicting an ordinal response for high-dimensional data
用于预测高维数据顺序响应的信息工具
  • 批准号:
    9273725
  • 财政年份:
    2012
  • 资助金额:
    $ 20.75万
  • 项目类别:
Informatic tools for predicting an ordinal response for high-dimensional data
用于预测高维数据顺序响应的信息工具
  • 批准号:
    8714054
  • 财政年份:
    2012
  • 资助金额:
    $ 20.75万
  • 项目类别:
Informatic tools for predicting an ordinal response for high-dimensional data
用于预测高维数据顺序响应的信息工具
  • 批准号:
    8216289
  • 财政年份:
    2012
  • 资助金额:
    $ 20.75万
  • 项目类别:
Recursive partitioning and ensemble methods for classifying an ordinal response
用于对序数响应进行分类的递归划分和集成方法
  • 批准号:
    7805045
  • 财政年份:
    2009
  • 资助金额:
    $ 20.75万
  • 项目类别:
Recursive partitioning and ensemble methods for classifying an ordinal response
用于对序数响应进行分类的递归划分和集成方法
  • 批准号:
    7670456
  • 财政年份:
    2008
  • 资助金额:
    $ 20.75万
  • 项目类别:

相似海外基金

Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 20.75万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 20.75万
  • 项目类别:
    Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 20.75万
  • 项目类别:
    Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 20.75万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 20.75万
  • 项目类别:
    Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 20.75万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 20.75万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 20.75万
  • 项目类别:
    Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 20.75万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
  • 批准号:
    484000
  • 财政年份:
    2023
  • 资助金额:
    $ 20.75万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了